1013099-50-7

Basic information

• Product Name: PYRIMIDINE, 5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-
• Synonyms: PYRIMIDINE, 5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-;5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-PYRIMIDINE
• CAS NO: 1013099-50-7
• Molecular Formula: C₁₁H₁₁BrClN₃
• Molecular Weight: 300.58214
• Mol File: 1013099-50-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PYRIMIDINE, 5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIMIDINE, 5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-(1013099-50-7)
• EPA Substance Registry System: PYRIMIDINE, 5-BROMO-4-CHLORO-2-(2,5-DIMETHYL-1H-PYRROL-1-YL)-6-METHYL-(1013099-50-7)

Safety Data

• Hazardous Substances Data: 1013099-50-7(Hazardous Substances Data)

Upstream product

• 6314-12-1 5-bromo-4-chloro-6-methylpyrimidin-2-ylamine 
• 110-13-4 2,5-hexanedione 
• 5600-21-5 2-amino-6-methyl-4-chloropyrimidine 

Downstream Products

• 1013099-51-8 trans-4-{[5-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methylpyrimidin-4-yl]amino}cyclohexanol 
• 1013099-80-3 cis-4-{[5-bromo-2-(2,5-dimethyl-1H-pyrrol-1-yl)-6-methylpyrimidin-4-yl]amino}cyclohexanol 
• 1013101-60-4 C₂₅H₂₆N₆O₃ 
• 1013101-61-5 C₂₁H₂₅N₇O₄ 
• 1013101-49-9 C₂₂H₂₅FN₆O₄ 
• 1013101-59-1 C₂₂H₂₆N₆O₄ 
• 1013101-58-0 C₂₅H₂₆N₆O₃ 
• 1013101-57-9 C₂₁H₂₅N₇O₄ 
• 1013101-54-6 C₂₂H₂₅FN₆O₄ 

Relevant articles and documents

Discovery of new thienopyrimidine derivatives as potent and orally efficacious phosphoinositide 3-kinase inhibitors

A series of new thienopyrimidine derivatives has been discovered as potent PI3K inhibitors. The systematic SAR studies for these analogues are described. Among them, 8a and 9a exhibit nanomolar enzymatic potencies and sub-micromolar cellular anti-prolifer

Protein Kinase Inhibitors

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts, hydrates, isomers, or solvates thereof, wherein the variables are described herein. The present invention further relates to pharmaceutical compositions which comprise the compounds of Formula I, and to methods for inhibiting protein kinase and methods of treating diseases, such as cancers, inflammation.